<?xml version="1.0" encoding="UTF-8"?>
<p id="Par3">Of several approved drugs, in two separate in vitro studies, chloroquine (CQ) and hydroxychloroquine (HCQ) showed potent antiviral activity against SARS-CoV-2 [
 <xref ref-type="bibr" rid="CR4">4</xref>]. Furthermore, a non-randomized, open label study in patients infected with the SARS-CoV-2 virus in Wuhan and other parts of China showed preliminary evidence of benefit against pneumonia and the clinical course of COVID-19 [
 <xref ref-type="bibr" rid="CR5">5</xref>]. This initial excitement was tempered by two large, retrospective observational trials involving HCQ which were unable to demonstrate efficacy in COVID-19 patients [
 <xref ref-type="bibr" rid="CR6">6</xref>, 
 <xref ref-type="bibr" rid="CR7">7</xref>]. Moreover, the use of HCQ was associated with a significantly higher risk for in-hospital death, cardiac arrest, and QT interval prolongation, and other electrocardiogram  abnormalities [
 <xref ref-type="bibr" rid="CR8">8</xref>–
 <xref ref-type="bibr" rid="CR10">10</xref>]. As a result of these safety concerns, the use of HCQ for anti-COVID-19 management has diminished.
</p>
